March 16 (Bloomberg) -- Medicis Pharmaceutical Corp.’s Reloxin, which would compete in the U.S. with Allergan Inc.’s best-selling Botox if approved by regulators, reduced the frown lines between eyebrows, a company-funded study found.
March 16 (Bloomberg) -- Medicis Pharmaceutical Corp.’s Reloxin, which would compete in the U.S. with Allergan Inc.’s best-selling Botox if approved by regulators, reduced the frown lines between eyebrows, a company-funded study found.
